Corixa on Bexxar

"Answers to many questions" raised by FDA in March 16 "complete review" letter for non-Hodgkin's therapy Bexxar "are now complete and we are focused on finishing final study reports for two of the three additional studies that we previously announced would be submitted to the agency," Corixa says June 20. "We are waiting the results of independent radiology and oncology reviews of response and duration of response data...We will file our response with the agency when the independent review data is final"